Mirdametinib Clinical Trials
10 recruitingDrug
Phase 210Phase 16
Showing 1–10 of 10 trials
Recruiting
Phase 2
Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
Recurrent Chronic Lymphocytic LeukemiaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic Leukemia+1 more
National Cancer Institute (NCI)20 enrolled3 locationsNCT07061951
Recruiting
Phase 1Phase 2
A Study of Mirdametinib in People With Central Nervous System Tumors
GliomaCentral Nervous System Tumors
Memorial Sloan Kettering Cancer Center26 enrolled7 locationsNCT07539441
Recruiting
Phase 1Phase 2
Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).
NF1Cutaneous NeurofibromaMonotherapy
Johns Hopkins University24 enrolled1 locationNCT06159166
Recruiting
Phase 1Phase 2
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma
Multiple MyelomaRelapsed and/or Refractory Multiple Myeloma (RRMM)
National Cancer Institute (NCI)54 enrolled1 locationNCT06876142
Recruiting
Phase 1Phase 2
A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
LiposarcomaDedifferentiated LiposarcomaPleomorphic Liposarcoma+6 more
Memorial Sloan Kettering Cancer Center54 enrolled7 locationsNCT06843967
Recruiting
Phase 2
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations
PI3K Gene MutationVascular AnomaliesArteriovenous Malformations+11 more
Murdoch Childrens Research Institute50 enrolled2 locationsNCT05983159
Recruiting
Phase 1Phase 2
Phase 1/2 Study of Mirdametinib + Vinblastine for Newly Diagnosed/Previously Untreated PLGG + Activation of MAPK
Pediatric Low-grade Glioma
St. Justine's Hospital50 enrolled5 locationsNCT06666348
Recruiting
Phase 1Phase 2
SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma
St. Jude Children's Research Hospital132 enrolled1 locationNCT04923126
Recruiting
Phase 2
Mirdametinib in Patients With Advanced NF1-mutant Melanoma
Metastatic MelanomaAdvanced Unresectable Melanoma
Kevin Kim, MD10 enrolled1 locationNCT07237100
Recruiting
Phase 2
Mirdametinib in Histiocytic Disorders
Histiocytic DisordersRosai-Dorfman Disease (RDD)Langerhans Cell Histiocytosis (LCH)+1 more
Children's Hospital Medical Center, Cincinnati40 enrolled1 locationNCT06153173